. 2016 Jul 7;6:29434. doi: 10.1038/srep29434

Table 1. Composition of patient-matched neoadjuvant breast tumour datasets used within our study.

Neoadjuvant treatment	n	Biopsy Time Interval/days		Extraction Method			Dataset/Reference
Neoadjuvant treatment	n	median	range	1^st	On-	Final	Dataset/Reference
None	37	27	13–53	CB	–	EB	This study
Letrozole	122	107	13–884	CB	CB	CB EB	Turnbull et al.¹³
Celecoxib/none	22 15	unspecified	14–21	CB	–	EB	(Brandão et al.²¹
Anastrozole	81 On-18 Final	14	14–112	CB	CB	CB	(Smith et al.⁵⁷
RAD001	21	14	14	CB	–	EB	(Sabine et al.⁵⁸
Anthracycline-based Chemotherapy	69	unspecified	unspecified	CB	CB	EB	(Magbanua et al.⁵⁹
None	56	14	14	CB		EB	Lopez-Knowles et al.⁴⁷